Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance

• Published in: European journal of histochemistry Vol. 66; no. 2
• Main Authors: Kong, Xin, Wang, Qi, Li, Jie, Li, Ming, Deng, Fusheng, Li, Chuanying
• Format: Journal Article
• Language: English
• Published: Italy PAGEPress Publications, Pavia, Italy 07-04-2022; PAGEPress Publications
• Subjects: Biomarkers, Tumor - metabolism; breast cancer; Breast Neoplasms - metabolism; Carrier Proteins - metabolism; epithelial growth factor receptor; ErbB Receptors - metabolism; Female; GATA-binding protein 3; GATA3 Transcription Factor - metabolism; Humans; Immunohistochemistry; mammaglobin; Mammaglobin A - metabolism; molecular subtype
• ISSN: 1121-760X; 2038-8306
• DOI: 10.4081/ejh.2022.3315

Increasing evidence has shown that mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) have unique clinical implications for breast cancer subtyping and classification, as well as for breast cancer targeted therapy. It is particularly important to clarify the correlation between their expression and different molecular breast carcinoma subtypes to better understand the molecular basis of the subtypes and to identify effective therapeutic targets for the disease. This study aimed to evaluate mammaglobin, GATA3, and EGFR expression in different breast cancer subtypes, as well as their clinical significance. Subjects of the study included 228 patients with breast cancer at The First Affiliated Hospital of University of Science and Technology of China. They were divided into triple negative (TN), Luminal A, Luminal B, and HER-2 positive (HER-2.P) breast cancer groups based on molecular classification. Immunohistochemical methods were used to detect mammaglobin, GATA3, and EGFR expression in cases of different molecular subtypes before determining the correlation between protein expression and subtype. Mammaglobin and GATA3 expression levels were found to significantly vary with respect to histopathological grade, lymph node status, and molecular subtype; EGFR expression was significantly correlated with breast cancer histopathological grade and molecular subtype. For breast cancer, the expression levels of mammaglobin and GATA3, as well as mammaglobin and EGFR, were significantly correlated. In addition, there was a significantly negative correlation between the expression levels of GATA3 and EGFR in breast cancer tissue samples, especially in HER-2.P samples. These findings provide a theoretical basis for assessing breast cancer clinical prognosis based on the cancer subtype, and hence, have significant practical value.